(Q37646066)

21 August 2017

1 reference

title

Viruses as vaccine vectors for infectious diseases and cancer (English)

1 reference

21 August 2017

0 references

1 reference

Simon J Draper

1

0 references

Jonathan L. Heeney

object named as

Jonathan L Heeney

series ordinal

2

0 references

language of work or name

English

0 references

publication date

1 January 2010

1 reference

Nature Reviews Microbiology

21 August 2017

1 reference

21 August 2017

8

1 reference

21 August 2017

1

1 reference

21 August 2017

62-73

1 reference

https://scigraph.springernature.com/pub.10.1038/nrmicro2240

21 August 2017

0 references

cites work

Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Live recombinant vaccinia virus protects chimpanzees against hepatitis B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Nonreplicating vaccinia vector efficiently expresses recombinant genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

NYVAC: a highly attenuated strain of vaccinia virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Vaccinia virus blocks Stat1-dependent and Stat1-independent gene expression induced by type I and type II interferons.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Viral evasion and subversion of pattern-recognition receptor signalling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

New insights into the subversion of the chemokine system by poxviruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Cowpox virus evades CTL recognition and inhibits the intracellular transport of MHC class I molecules

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Pathogen evasion strategies for the major histocompatibility complex class I assembly pathway.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Modified vaccinia virus ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Reduction of vector gene expression increases foreign antigen-specific CD8+ T-cell priming

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Intracellular cytokine optimization and standard operating procedure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Effective induction of high-titer antibodies by viral vector vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

A vaccine strategy utilizing a combination of three different chimeric vectors which share specific vaccine antigens.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Vaccine protection from CD4+ T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Kinetics of recombinant adenovirus type 5, vaccinia virus, modified vaccinia ankara virus, and DNA antigen expression in vivo and the induction of memory T-lymphocyte responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Role of viral factor E3L in modified vaccinia virus ankara infection of human HeLa Cells: regulation of the virus life cycle and identification of differentially expressed host genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Adenoviruses as vaccine vectors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Chimpanzee-origin adenovirus vectors as vaccine carriers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Replication-defective vector based on a chimpanzee adenovirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Direct priming and cross-priming contribute differentially to the induction of CD8+ CTL following exposure to vaccinia virus via different routes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Viral sequestration of antigen subverts cross presentation to CD8(+) T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Targeting lentiviral vectors to specific cell types in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Engineered lentivector targeting of dendritic cells for in vivo immunization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Current Status of Veterinary Vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Strategies and challenges for eliciting immunity against avian influenza virus in birds.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

A combination in-ovo vaccine for avian influenza virus and Newcastle disease virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Global FMD control--is it an option?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Rapid protection of cattle from direct challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus-vectored FMDV subunit vaccine.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Delivery of a foot-and-mouth disease virus empty capsid subunit antigen with nonstructural protein 2B improves protection of swine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Tuberculosis vaccines: present and future

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Immune responses induced in cattle by vaccination with a recombinant adenovirus expressing Mycobacterial antigen 85A and Mycobacterium bovis BCG

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guérin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Cattle as a model for development of vaccines against human tuberculosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Viral vectors in malaria vaccine development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Pre-erythrocytic malaria vaccines: towards greater efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Yellow fever vaccine: past, present and future

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Traditional and novel approaches to flavivirus vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Construction and characterization of recombinant flaviviruses bearing insertions between E and NS1 genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Cytotoxic T-cell immunity to influenza.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Immunological correlates of protection from HIV infection and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Acceptability of A-CASI by HIV-positive IDUs in a multisite, randomized, controlled trial of behavioral intervention (INSPIRE).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade Bgag/pol/nefVaccine in Healthy Adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Cancer vaccines: on the threshold of success

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

CD8+ T-Cell Tolerance can be Broken by an Adenoviral Vaccine While CD4+ T-Cell Tolerance is Broken by Additional Co-administration of a Toll-Like Receptor Ligand

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRMICRO2240

31 March 2020

12 December 2020

Immunogenicity and safety of a DNA prime/adenovirus boost vaccine against rhesus CEA in nonhuman primates

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Engineering of a vaccinia virus bacterial artificial chromosome in Escherichia coli by bacteriophage lambda-based recombination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Application of non-structural protein antibody tests in substantiating freedom from foot-and-mouth disease virus infection after emergency vaccination of cattle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

The formation and function of extracellular enveloped vaccinia virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

CD46 is a cellular receptor for group B adenoviruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Human adenovirus cloning vectors based on infectious bacterial plasmids.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

A natural vaccinia virus promoter with exceptional capacity to direct protein synthesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges

31 March 2020

1 reference

12 December 2020

Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.

1 reference

12 December 2020

HIV vaccine development: Lessons from the past, informing the future.

1 reference

12 December 2020

Evasion of the immune system by adenoviruses.

1 reference

12 December 2020

Lessons learned from a review of the development of selected vaccines. National Vaccine Advisory Committee.

1 reference

12 December 2020

Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States

1 reference

12 December 2020

Technical challenges facing therapeutic cancer vaccines

1 reference

12 December 2020

Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara.

1 reference

12 December 2020

A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.

1 reference

12 December 2020

An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2240

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/NRMICRO2240

1 reference

21 August 2017

1 reference

PubMed ID

19966816